Clinical Trial Detail

NCT ID NCT03371017
Title A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer (IMpassion132)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

triple-receptor negative breast cancer

Therapies

Atezolizumab + Capecitabine + Carboplatin + Gemcitabine

Capecitabine + Carboplatin + Gemcitabine

Age Groups: senior adult

No variant requirements are available.